All News

Nivolumab was previously granted accelerated approval by the FDA for the treatment of patients with small cell lung cancer (SCLC) whose disease had progressed after platinum-based chemotherapy and at least 1 other line of therapy, but phase 3 trial results led to a decision to withdraw the indication.

Combination treatment with telaglenastat (CB-839) and cabozantinib (Cabometyx) did not meet the study’s primary end point of improved progression-free survival versus cabozantinib alone in patients with advanced or metastatic clear cell renal cell carcinoma.

Under the FDA’s Real-Time Oncology Review Pilot Program and Project ORBIS, the FDA is reviewing a supplemental new drug application for lorlatinib (Lorbrena) as a first-line treatment for patients with ALK-positive metastatic non–small cell lung cancer.

Murphy discussed the secondary end point of equivocal findings on PSMA PET/CT from the proPSMA study presented at the SUO 21st Annual Meeting.

The director of clinical research in the Center for Cancer Care at White Plains Hospital spoke about the implications of a study which evaluated the impact of diabetes in patients with multiple myeloma.

An expert in urologic oncology seeks to answer further questions regarding the use of telemedicine for this patient population.

Short described the importance of the time point of CR outcomes for patients treated as part of an ALL study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Ghobadi expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 ASH Annual Meeting.

Wolf touched on the future of MRD and the potential development of more sensitive measuring techniques for patients with multiple myeloma.

The breast cancer expert discussed the latest developments in breast cancer research and what she hopes the next year will offer this patient population.

Guido Lancman, MD, sought to evaluate the effect of intravenous immunoglobulin on infections in patients with multiple myeloma receiving daratumumab.

Vikram Narayan, MD, details the little-known fact that tobacco cessation is a leading preventative strategy of bladder cancer recurrence.

Treatment with olaparib versus physician’s choice of standard therapy led to a significantly longer duration of overall survival in patients with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1/2 or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.

The preliminary findings of the extension arm of the phase 1b/2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma.

The leukemia expert discussed the clinical implications of findings demonstrating improved response for patients with acute myeloid leukemia with IDH mutations.

Declan Murphy, MB, BCh, shares his thoughts on the potential for prostate-specific membrane antigen PET/CT to impact outcomes for patients with localized and high-risk prostate cancers.

Among women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year resulted in significantly improved disease-free survival rates compared with observation.

Clinician Lisa La sought to evaluate differences in baseline characteristics, treatment patterns, and survival outcomes in patients with diabetes versus those without who were enrolled in the CONNECT MM Registry.

Study results indicated that the small molecule HIF-2α inhibitor MK-6482 induced positive results in patients with certain Von Hippel-Lindau disease–associated solid tumors.

The myeloma expert discussed the importance of sustained MRD negativity for patients with multiple myeloma treated with daratumumab (Darzalex).

“Although previous trials demonstrated that the prior version of the DNA-RNA test was more specific than the prior version of the RNA test, the current molecular test techniques have no statistically significant difference in performance,” wrote Masha J. Livhits, MD, and colleagues.

The medical oncologist at the Mayo Clinic in Phoenix, spoke about the progress seen in gastrointestinal cancer research in 2020, as well as what improvements he hopes will occur in 2021.

Study results revealed the impact of a rurally focused telemedicine program on patient outcomes.

Short discussed currently available assays for MRD detection, blinatumomab treatment, and other implications from an ALL study presented at the 2020 ASH Annual Meeting.

The results of one study suggested that older adults with advanced cancer may be at a higher risk for financial toxicity compared with those undergoing treatments for other chronic conditions.

Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

“These findings suggest that similar to its benefits in ovarian cancer, NACT could potentially lower perioperative morbidity and may serve as an important treatment option among women with metastatic endometrial cancer,” the study authors wrote.

Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.

This study indicated that appendiceal cancer diagnosed among younger individuals harbors a distinct genomic landscape, as compared with appendiceal cancer diagnosed among older individuals.

A study of the effect of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab indicated that hypogammaglobulinemia was nearly universal during treatment, suggesting a role for IVIG.